Special collections

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
Howard Jack West, Mark McCleland, Federico Cappuzzo, Martin Reck, Tony SK Mok, Robert M Jotte, Makoto Nishio, Eugene Kim, Stefanie Morris, Wei Zou, David Shames, Meghna Das Thakur, Geetha Shankar, Mark A Socinski

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e003027; DOI: 10.1136/jitc-2021-003027
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
Solange Peters, Luis Paz-Ares, Roy S Herbst, Martin Reck

Journal for ImmunoTherapy of Cancer Jul 2022, 10 (7) e004863; DOI: 10.1136/jitc-2022-004863
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Javier Glez-Vaz, Arantza Azpilikueta, Irene Olivera, Assunta Cirella, Alvaro Teijeira, Maria C Ochoa, Maite Alvarez, Iñaki Eguren-Santamaria, Carlos Luri-Rey, Maria E Rodriguez-Ruiz, Xinxin Nie, Lieping Chen, Sonia Guedan, Miguel F Sanmamed, Jose Luis Perez Gracia, Ignacio Melero

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003532; DOI: 10.1136/jitc-2021-003532
Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway
Ye Shen, Jason S Eng, Flordeliza Fajardo, Lingming Liang, Cong Li, Patrick Collins, Donato Tedesco, Olivier Nolan-Stevaux

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e004348; DOI: 10.1136/jitc-2021-004348
CD8⁺PD-1⁺ to CD4⁺PD-1⁺ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
Boris Duchemann, Marie Naigeon, Edouard Auclin, Roberto Ferrara, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, François-Xavier Danlos, Laura Mezquita, Caroline Caramella, Aurelien Marabelle, Benjamin Besse, Nathalie Chaput

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e004012; DOI: 10.1136/jitc-2021-004012
Lipid-loaded macrophages as new therapeutic target in cancer
Giulia Marelli, Nicolò Morina, Federica Portale, Marta Pandini, Marta Iovino, Giusy Di Conza, Ping-Chih Ho, Diletta Di Mitri

Journal for ImmunoTherapy of Cancer Jul 2022, 10 (7) e004584; DOI: 10.1136/jitc-2022-004584
ISA101 and nivolumab for HPV-16⁺ cancer: updated clinical efficacy and immune correlates of response
Luana Guimaraes de Sousa, Kimal Rajapakshe, Jaime Rodriguez Canales, Renee L Chin, Lei Feng, Qi Wang, Tomas Z Barrese, Erminia Massarelli, William William, Faye M Johnson, Renata Ferrarotto, Ignacio Wistuba, Cristian Coarfa, Jack Lee, Jing Wang, Cornelis J M Melief, Michael A Curran, Bonnie S Glisson

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e004232; DOI: 10.1136/jitc-2021-004232
NIR fluorescence imaging and treatment for cancer immunotherapy
Homan Kang, Min-Woong Kang, Satoshi Kashiwagi, Hak Soo Choi

Journal for ImmunoTherapy of Cancer Jul 2022, 10 (7) e004936; DOI: 10.1136/jitc-2022-004936
Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy
Jianjun Hu, Jiangyi He, Yunlong Wang, Yang Zhao, Kejing Fang, Yan Dong, Yanrong Chen, Yue Zhang, Chi Zhang, Hongwei Wang, Jun Tan, Junyi Wang, Ruiyang Zi, Chengxiang Liu, Houjie Liang, Yanli Guo, Juanjuan Ou

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003408; DOI: 10.1136/jitc-2021-003408
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
Huanpeng Chen, Yuying Yang, Yuqing Deng, Fengjiao Wei, Qingyu Zhao, Yongqi Liu, Zhonghua Liu, Bolan Yu, Zhaofeng Huang

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e003737; DOI: 10.1136/jitc-2021-003737

Main menu

Special collections

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Special collections

Pages